Category: Finance | Title: Ibuprofen Recall 2019: Latest Facts on Safety Alerts, Companies, and FDA Actions | Tag: ibuprofen recall | Meta Description: Key facts on the ibuprofen recall 2019, including companies, FDA actions, lot numbers, and consumer safety guidance...
What Happened in the Ibuprofen Recall 2019
In 2019, several manufacturers issued voluntary recalls of ibuprofen products after quality testing raised concerns about impurities and labeling accuracy. The U.S. Food and Drug Administration posted public notifications listing affected lot numbers, dosage strengths, and distribution channels, helping pharmacies and consumers identify potentially impacted packages. FDA Recall Database
Recalls typically followed a classification system ranging from Class I, where use could cause serious health risks, to Class III, where violations were unlikely to cause adverse health consequences. Companies such as Perrigo, Aurobindo Pharma, and other generic drug manufacturers were among those who publicly disclosed recalls during this period, citing deviations in dissolution testing, microbial limits, or packaging defects that could affect product integrity.
Which Companies and Products Were Affected
Major retailers including Walmart, CVS, and Walgreens removed select ibuprofen items from shelves after receiving recall notices from their suppliers. Store-brand ibuprofen tablets, capsules, and liquid gels were among the products pulled, with specific lot numbers and expiration dates listed in FDA enforcement reports and company press releases.
Common Reasons for the 2019 Recalls
Reasons cited in the recalls included failure to meet dissolution specifications, which can affect how quickly the drug releases in the body, and the presence of residual solvents or impurities above acceptable thresholds. Some recalls also involved mislabeled dosage instructions or packaging that did not meet child-resistant standards, prompting firms to issue corrections to protect patient safety.
How Consumers and Regulators Responded
Consumers were advised to check their medicine cabinets for affected lot numbers and to discontinue use of any product matching the recall notices. Pharmacists played a key role in identifying returns and replacements, while the FDA updated its website with searchable recall tables and safety alerts to help the public verify whether specific products were part of the action.
Industry analysts noted that the recalls temporarily affected consumer confidence in store-brand pain relievers, with some shoppers switching to name-brand alternatives or other active ingredients such as naproxen. Regulatory filings and earnings reports from the involved manufacturers highlighted the costs of quality control improvements and the importance of compliance with Current Good Manufacturing Practices to prevent future disruptions.